

# Improving symptoms of intermittent claudication in patients with erectile dysfunction and peripheral vascular disease: a pilot study assessing the benefit of daily dosing with Cialis (tadalafil) 10 mg

<b>Submission date</b> 18/09/2007	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 05/12/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 10/07/2017	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English Summary

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Dr Graham Jackson

### Contact details

Cardiothoracic Centre  
6th Floor, East Wing  
St Thomas' Hospital  
London  
United Kingdom  
SE1 7EH  
+44 (0)20 7188 1055  
jean.stagg@gstt.nhs.uk

## Additional identifiers

EudraCT/CTIS number

IRAS number

**ClinicalTrials.gov number**

**Secondary identifying numbers**

GJ001 PVD

## **Study information**

### **Scientific Title**

Improving symptoms of intermittent claudication in patients with erectile dysfunction and peripheral vascular disease: a pilot study assessing the benefit of daily dosing with Cialis (tadalafil) 10 mg

### **Study hypothesis**

Daily dosing with the Phosphodiesterase type 5 (PDE 5) inhibitor tadalafil (10 mg) (for a 14-day period) may improve symptoms of claudication in patients with erectile dysfunction and peripheral vascular disease.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

St Thomas' Hospital Local Research Ethics Committee, 09/01/2007, ref: 06/Q0702/162

### **Study design**

Prospective randomised double-blind placebo-controlled cross-over pilot study

### **Primary study design**

Interventional

### **Secondary study design**

Randomised cross over trial

### **Study setting(s)**

Hospital

### **Study type(s)**

Treatment

### **Participant information sheet**

Not available in web format, please use the contact details to request a patient information sheet

### **Condition**

Erectile dysfunction, peripheral vascular disease

### **Interventions**

Suitably screened and consenting patients will undertake an Exercise Tolerance Test (ETT) (modified Bruce protocol). Once baseline is established (two tests, 2 weeks apart), Tadalafil 10 mg daily or placebo will be prescribed for a 14 day period. ETT will then be repeated. A weeks wash-out will be observed. A repeat ETT will be undertaken and the patient prescribed either

placebo or tadalafil for a further 14 day period. ETT will be repeated. A final follow up occurs one week after this, and with a one week run in, this makes the total duration of this study 7 weeks.

**Intervention Type**

Drug

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Tadalafil

**Primary outcome measure**

Total number of minutes/seconds on the exercise treadmill. Time to first report of leg pain will be recorded, measured at the end of weeks 3, 4 and 6

**Secondary outcome measures**

Change in score on the Walking Impairment Questionnaire and the Peripheral Artery Disease Symptom Scale, measured at the end of weeks 3, 4 and 6

**Overall study start date**

19/09/2007

**Overall study end date**

01/04/2008

**Eligibility****Participant inclusion criteria**

1. Male aged 40 - 80 years
2. Erectile dysfunction (Sexual Health Inventory for Men [SHIM] score less than 21)
3. Peripheral vascular disease (PVD) (confirmed by previous ultrasound studies)

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Male

**Target number of participants**

20

**Participant exclusion criteria**

1. Contraindication to PDE 5 inhibitor
2. Inability to undertake an exercise tolerance test

**Recruitment start date**

19/09/2007

**Recruitment end date**

01/04/2008

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**St Thomas' Hospital**

London

United Kingdom

SE1 7EH

## Sponsor information

**Organisation**

Guy's and St Thomas' NHS Foundation Trust (UK)

**Sponsor details**

Research and Development Office

Floor 3, Coneybeare House

Guy's Hospital

St Thomas' Street

London

England

United Kingdom

SE1 9RT

+44 (0)20 7188 5733

kate.blake@gstt.nhs.uk

**Sponsor type**

Hospital/treatment centre

**Website**

<http://www.guysandstthomas.nhs.uk/>

**ROR**

<https://ror.org/00j161312>

# **Funder(s)**

## **Funder type**

Charity

## **Funder Name**

The Friend's of Guy's Hospital (UK)

# **Results and Publications**

## **Publication and dissemination plan**

Not provided at time of registration

## **Intention to publish date**

## **Individual participant data (IPD) sharing plan**

## **IPD sharing plan summary**

Not provided at time of registration